Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward
This article was originally published in PharmAsia News
Executive Summary
The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose instead of three.